Drug Discovery 2022: driving the next life science revolution
Pelago Bioscience AB
Where: D4 [Show on Floor Plan]
The CEllular Thermal Shift Assay (CETSA) allows a direct quantification of drug target engagement in living cells and tissues. The biophysical basis of the method enables a label free approach on the native endogenously expressed target in situ. Because of the generic format and the physiological relevance of CETSA, Pelago Bioscience has implemented multiple applications in Drug Discovery. Since the first publication of the CETSA method it has been used for orthogonal measures of drug occupancy adding real value to existing efficacy assays on more than 70 drug targets in multiple therapy areas. The examples of CETSA utility ranges from Target ID and validation, lead generation and drug candidate profiling to translational science and rational biomarker discovery.
Tel: +46(0)769410187
Address: Banvaktsvägen 20
171 48 Solna
Website: http://www.pelagobio.com
Email: info@pelagobio.com

Presentations at Drug Discovery 2022: driving the next life science revolution

Staff Attending

Dr Jakub Lewicki
Key Account Manager
Pelago Bioscience AB